Datasheet is currently unavailable. Try again or CONTACT US

Recombinant Anti-VEGF RTH258 scFv Antibody

50 µg
Liquid (sterile filtered)
Chinese Hamster
$489.00 /Per Item
Availability: Ships next business day
Shipping info:

$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.


VEGF is a potent mitogen in embryonic and somatic angiogenesis with specificity for vascular endothelial cells. VEGF forms homodimers and exists in four different isoforms. Overall, the VEGF monomer resembles that of PDGF, but its N-terminal segment is helical rather than extended. VEGF shares homologies of about 21% and 24% respectively with the A and B chains of human platelet-derived growth factor (PDGF), and has complete conservation of the eight cysteine residues found in both mature PDGF chains. The cysteine knot motif is a common feature of this domain. The homology is not reflected in function, however, since the cell types responsive to VEGF are distinct from those responsive to homo- and heterodimers of the PDGF chains. This protein is a glycosylated mitogen that acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. VEGF-A also has been shown to have effects on a number of other cell types (e.g. stimulation of monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). VEGF-A is also a vasodilator; it increases microvascular permeability, and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Antibody against VEGF-A (Bevacizumab or brand name Avastin) is approved for treatment of cancer by inhibiting angiogenesis. Ranibizumab, a Fab fragment of Avastin or so-called Lucentis is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. This antibody has its amino acid sequence like one of Brolucizumab (sold under trade names Beovu or Vsiqq) - a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Product Details

Humanized Recombinant Anti-Human VEGF RTH258 scFv Antibody - 400-001-MT5
Anti-VEGF-A Antibody, RTH258, Brolucizumab, Vascular endothelial growth factor A, VEGF A, VEGFA, Vascular permeability factor, VPF
Chinese Hamster
Recombinant Monoclonal

Target Details

VEGF-A  - View All VEGF-A Products
Recombinant Protein
Humanized Recombinant anti-VEGFA ScFV fragment was expressed in CHO cells. The purity was estimated to be >90% by SDS-PAGE analysis.

Application Details

Humanized Recombinant Anti-VEGFA ScFV fragment Antibody has been tested for use in Flow Cytometry, Western Blot, and ELISA. This antibody recognizes structured VEGF-A and will work in western blot when the protein has not been denatured with DTT or bMe. Although not tested, this antibody could be useful in in IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user


0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
30% Glycerol

Shipping & Handling

Wet Ice
Store vial at 2-8° C. Dilute only prior to immediate use.
Expiration date is six (6) months from date of receipt.

Invalid lot number

If you need help finding your CoA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

Related products to: Recombinant Anti-VEGF RTH258 scFv Antibody